Yongliang Yang

Yongliang Yang

Auto-generated profile, based on publicly available information

Yongliang Yang

Dalian University of Technology

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZHZhi-Jie Hou
Zhi-Jie Hou
XLXi Luo
Xi Luo
WZWei Zhang
Wei Zhang
FPFei Peng
Fei Peng
BCBai Cui
Bai Cui
QLQuentin Liu
Quentin Liu
Cancer stem-like cell (CS-like cell) is considered to be responsible for recurrence and drug resistance events in breast cancer, which makes it a potential target for novel cancer therapeutic strategy. The FDA approved flubendazole, has been widely used in the treatment of intestinal parasites. Here, we demonstrated a novel effect of flubendazole on breast CS-like cells. Flubendazole inhibited breast cancer cells proliferation in dose- and time-dependent manner and delayed tumor growth in xenograft models by intraperitoneal injection. Importantly, flubendazole reduced CD44high/CD24low subpopulation and suppressed the formation of mammosphere and the expression of self-renewal related genes including c-myc, oct4, sox2, nanog and cyclinD1. Moreover, we found that flubendazole induced cell differentiation and inhibited cell migration. Consistently, flubendazole reduced mesenchymal markers (β-catenin, N-cadherin and Vimentin) expression and induced epithelial and differentiation marker (Keratin 18) expression in breast cancer cells. Mechanism study revealed that flubendazole arrested cell cycle at G2/M phase and induced monopolar spindle formation through inhibiting tubulin polymerization. Furthermore, flubendazole enhanced cytotoxic activity of conventional therapeutic drugs fluorouracil and doxorubicin against breast cancer cells. In conclusion, our findings uncovered a remarkable effect of flubendazole on suppressing breast CS-like cells, indicating a novel utilization of flubendazole in breast cancer therapy.

1 January 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HWHaijun Wen
Haijun Wen
HMHuajuan Ma
Huajuan Ma
QCQichun Cai
Qichun Cai
SLSuxia Lin
Suxia Lin
XLXinxing Lei
Xinxing Lei
QLQuentin Liu
Quentin Liu

5 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJiawen Bu
Jiawen Bu
YZYixiao Zhang
Yixiao Zhang
SWSijin Wu
Sijin Wu
HLHaonan Li
Haonan Li
LSLisha Sun
Lisha Sun
CLCaigang Liu
Caigang Liu
Failure to achieve complete elimination of triple negative breast cancer (TNBC) stem cells after adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast cancer stem cells (BCSCs), and its enzymatic activity regulates tumor stemness. Identifying upstream targets to control ALDH+ cells may facilitate TNBC tumor suppression. Here, we show that KK-LC-1 determines the stemness of TNBC ALDH+ cells via binding with FAT1 and subsequently promoting its ubiquitination and degradation. This compromises the Hippo pathway and leads to nuclear translocation of YAP1 and ALDH1A1 transcription. These findings identify the KK-LC-1-FAT1-Hippo-ALDH1A1 pathway in TNBC ALDH+ cells as a therapeutic target. To reverse the malignancy due to KK-LC-1 expression, we employ a computational approach and discover Z839878730 (Z8) as an small-molecule inhibitor which may disrupt KK-LC-1 and FAT1 binding. We demonstrate that Z8 suppresses TNBC tumor growth via a mechanism that reactivates the Hippo pathway and decreases TNBC ALDH+ cell stemness and viability.

2 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWen Su
Wen Su
SWSijin Wu
Sijin Wu
YYYongliang Yang
Yongliang Yang
YGyanlin Guo
yanlin Guo
HZHaibo Zhang
Haibo Zhang
YGYoufei Guan
Youfei Guan
17β-hydroxysteroid dehydrogenase-13 is a hepatocyte-specific, lipid droplet-associated protein. A common loss-of-function variant ofHSD17B13(rs72613567: TA) protects patients against non-alcoholic fatty liver disease with underlying mechanism incompletely understood. In the present study, we identify the serine 33 of 17β-HSD13 as an evolutionally conserved PKA target site and its phosphorylation facilitates lipolysis by promoting its interaction with ATGL on lipid droplets. Targeted mutation of Ser33 to Ala (S33A) decreases ATGL-dependent lipolysis in cultured hepatocytes by reducing CGI-58-mediated ATGL activation. Importantly, a transgenic knock-in mouse strain carrying theHSD17B13S33A mutation (HSD17B1333A/A) spontaneously develops hepatic steatosis with reduced lipolysis and increased inflammation. Moreover,Hsd17B1333A/Amice are more susceptible to high-fat diet-induced nonalcoholic steatohepatitis. Finally, we find reproterol, a potential 17β-HSD13 modulator and FDA-approved drug, confers a protection against nonalcoholic steatohepatitis via PKA-mediated Ser33 phosphorylation of 17β-HSD13. Therefore, targeting the Ser33 phosphorylation site could represent a potential approach to treat NASH.

28 August 2018 in ACS Sensors
Verified
Journal Article
Closed access
LFLei Feng
Lei Feng
YYYongliang Yang
Yongliang Yang
XHXiaokui Huo
Xiaokui Huo
XTXiangge Tian
Xiangge Tian
YFYujie Feng
Yujie Feng
XMXiaochi Ma
Xiaochi Ma

9 January 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MLMing Li
Ming Li
JGJiali Gao
Jiali Gao
YTYan Tang
Yan Tang
MLMeishuo Liu
Meishuo Liu
SWSijin Wu
Sijin Wu
YYYongliang Yang
Yongliang Yang
Sulforaphene (LFS-01) is a natural compound derived from traditional herbal medicine. Here, we show that oral administration of LFS-01 is able to dramatically alter the skewed gut microbiota and reverse colitis in model mice associated with an increase of intestinal γδT cells. Through 16S rDNA sequencing, we showed that LFS-01 can selectively suppress enteric pathogens such as Escherichia–Shigella and Helicobacter whereas the protective strains including Lactobacillus and Lachnospiraceae were significantly expanded after LFS-01 treatment. Interestingly, we demonstrated that LFS-01 administration can significantly promote the IL-17+γδT cells in model mice in response to the expanded Lactobacillus. We verified that the intracellular components of Lactobacillus can stimulate the growth of IL-17+γδT cells upon preincubation. The increased IL-17A after LFS-01 treatment in turn recovers the disrupted occludin subcellular location and protects the epithelial barrier in the colon of model mice. Remarkably, LFS-01 does not show apparent toxicity to animals and we demonstrated that LFS-01 also exerts strong protective effects in TNBS-induced colitis rats. Therefore, LFS-01 holds great promise for the treatment of inflammatory bowel disease (IBD) and warrants translation for use in clinical trials. Our work provided a new avenue for the treatment of IBD based on the strategy of harnessing intestinal symbiosis.